Publication Name	World Journal of Clinical Cases
Manuscript ID	98179
Country	China

Received	2024-06-19 14:28
Peer-Review Started	2024-06-19 14:28
To Make the First Decision
Return for Revision	2024-08-01 00:59
Revised	2024-08-02 03:53
Second Decision	2024-08-13 03:01
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-08-13 09:19
Articles in Press	2024-08-13 09:19
Publication Fee Transferred
Edit the Manuscript by Language Editor	2024-08-15 07:41
Typeset the Manuscript	2024-08-23 00:30
Publish the Manuscript Online	2024-09-24 02:54

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Editorial
Article Title	Advanced lung adenocarcinoma with EGFR 19-del mutation transforms into squamous cell carcinoma after EGFR-tyrosine kinase inhibitors treatment
Manuscript Source	Invited Manuscript
All Author List	Ruo-Bing Qi and Zheng-Hao Wu
ORCID	Author(s) ORCID Number Ruo-Bing Qi http://orcid.org/0000-0002-4471-2726 Zheng-Hao Wu http://orcid.org/0000-0001-8468-1234
Funding Agency and Grant Number
Corresponding Author	Zheng-Hao Wu, MD, Doctor, Doctor, Research Associate, Surgeon, Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Avenue, Wuhan 430022, Hubei, China. 421910799@qq.com
Key Words	Lung adenocarcinoma; Squamous cell carcinoma; Pathological histological transformation; Epidermal growth factor receptor tyrosine kinase inhibitor; Drug resistance
Core Tip	Patients will inevitably face resistance issues after treatment with EGFR-tyrosine kinase inhibitors (TKIs), and resistance to EGFR-TKIs can be divided into primary and acquired. Pathological transformation is one of the mechanisms of acquired resistance to EGFR-TKIs, with the transformation to squamous cell carcinoma being relatively rare. This case report provides detailed information on a 67-year-old female patient with advanced lung adenocarcinoma and an EGFR 19 del mutation, who developed resistance after treatment with EGFR-TKIs.
Publish Date	2024-09-24 02:54
Citation	<p>Qi RB, Wu ZH. Advanced lung adenocarcinoma with EGFR 19-del mutation transforms into squamous cell carcinoma after EGFR-tyrosine kinase inhibitors treatment. <i>World J Clin Cases</i> 2024; 12(32): 6543-6546</p>
URL	https://www.wjgnet.com/2307-8960/full/v12/i32/6543.htm
DOI	https://dx.doi.org/10.12998/wjcc.v12.i32.6543

Full Article (PDF)	WJCC-12-6543-with-cover.pdf
Manuscript File	98179_Auto_Edited_025827.docx
Answering Reviewers	98179-answering-reviewers.pdf
Audio Core Tip	98179-audio.m4a
Conflict-of-Interest Disclosure Form	98179-conflict-of-interest-statement.pdf
Copyright License Agreement	98179-copyright-assignment.pdf
Non-Native Speakers of English Editing Certificate	98179-non-native-speakers.pdf
Peer-review Report	98179-peer-reviews.pdf
Scientific Misconduct Check	98179-scientific-misconduct-check.png
Scientific Editor Work List	98179-scientific-editor-work-list.pdf
CrossCheck Report	98179-crosscheck-report.png
CrossCheck Report	98179-crosscheck-report.pdf